<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We present the case of a 37-year-old woman with severe refractory colonic and perianal <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> who had lost response to second-line, steroid-sparing treatments <z:chebi fb="2" ids="2948">azathioprine</z:chebi>, <z:chebi fb="0" ids="44185">methotrexate</z:chebi> and infliximab </plain></SENT>
<SENT sid="1" pm="."><plain>For many such patients extensive surgery has often been considered the only option </plain></SENT>
<SENT sid="2" pm="."><plain>New insights provided by the results of genome-wide association scanning in <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> highlight autophagy, a cellular process implicated in the clearance of intracellular bacteria, as a key process in <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> pathogeneses </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="9168">Sirolimus</z:chebi> (<z:chebi fb="0" ids="9168">rapamycin</z:chebi>) is a drug used to upregulate autophagy in cell culture in the laboratory, and in clinical practice to prevent rejection following organ transplantation due to independent immunosuppressive action </plain></SENT>
<SENT sid="4" pm="."><plain>Our patient was treated with <z:chebi fb="0" ids="9168">sirolimus</z:chebi> for 6 months at a dose that maintained serum trough levels of 5 ng/ml </plain></SENT>
<SENT sid="5" pm="."><plain>There was marked and sustained improvement in <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> symptoms with the Harvey-Bradshaw index falling from 13 to 3, in serum markers of <z:mp ids='MP_0001845'>inflammation</z:mp> (C-reactive protein fell from 79 to 2) and endoscopic appearance </plain></SENT>
<SENT sid="6" pm="."><plain>This is the first reported case of the use of <z:chebi fb="0" ids="9168">sirolimus</z:chebi> to treat <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> </plain></SENT>
</text></document>